Moreover, MET gene amplification has been recognized as a mechanism of resistance to EGFR inhibitors in metastatic colorectal cancer and non-small-cell lung cancer (NSCLC) [32,33,34]. Here, EGFR is linked to non-small cell lung carcinoma.